On Thursday, Giga-tronics, Incorporated (NASDAQ:GIGA)’s shares declined -25.80% to $2.10.
Giga-tronics, Incorporated (GIGA) will release results for the fourth quarter of fiscal year 2015 on Monday, May 18, 2015 after the close of trading on the NASDAQ Capital Market.
Also on Monday, May 18, 2015, Giga-tronics will host a conference call at 4:30 p.m. EDT to talk about the results and provide an update on Company operations.
Giga-tronics Incorporated, together with its auxiliaries, designs, manufactures, and markets a range of test and measurement equipment used in the development, testing, and maintenance of wireless communications products and systems, flight navigational equipment, electronic defense systems, and automatic testing systems.
Discovery Laboratories, Inc. (NASDAQ:DSCO)’s shares dropped -19.99% to $0.920.
Discovery Laboratories, Inc. (DSCO) stated top line data from its recently accomplished AEROSURF® phase 2a clinical trial in premature infants with respiratory distress syndrome (RDS). Key objectives of the study were achieved, counting (1) the primary objective of demonstrating the safety and tolerability of a single exposure of aerosolized KL4 surfactant administered in three escalating inhaled doses to premature infants 29 to 34 week gestational age and receiving nasal continuous positive airway pressure (nCPAP) for RDS, contrast to infants receiving nCPAP alone, and (2) establishing proof of concept for the Company’s proprietary technology platform based on physiological data suggesting that aerosolized KL4 surfactant is being delivered into the lung of premature infants, and acceptable performance of the novel capillary aerosol generator (CAG) technology in the neonatal intensive care unit (NICU).
Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), in addition to develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant.
At the end of Thursday’s trade, Puma Biotechnology Inc (NYSE:PBYI)‘s shares dipped -18.73% to $170.67.
Puma Biotechnology Inc (PBYI) declared the release of four abstracts on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 to June 2, 2015, in Chicago.
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer.
Kandi Technologies Group Inc (NASDAQ: KNDI), ended its Thursday’s trading session with -14.11% loss, and closed at $9.07.
Kandi Technologies Group Inc (KNDI) declared its financial results for the quarter ended March 31, 2015.
2015 First Quarter Highlights
Total revenues grew 9.0% to $43.8 million for the first quarter of 2015 from $40.2 million for the first quarter of 2014;
Electric Vehicle (“EV”) Parts sales raised by 71.3% to $43.0 million for the first quarter of 2015 contrast to $25.1 million in the same period of 2014;
The first quarter sales for our joint venture company, Kandi Electric Vehicles Group Co., Ltd. (the “JV Company”)1, were $30.6 million, with net income of $0.8 million. Based on Kandi’s 50% equity ownership in the JV Company, Kandi recorded $0.5 million in net income (after tax and intra-entity elimination) for the first quarter of 2015;
The JV Company sold 1,670 EV products during the first quarter of 2015, 37.4% enhance contrast to 1,215 EV products sold in the same quarter of 2014
Kandi Technologies Group, Inc., through its auxiliaries, designs, develops, manufactures, and commercializes electric vehicles (EVs), EV parts, and off-road vehicles in the Peoples Republic of China and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
